Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AWAWU E IGBINADOLOR

Allopathic & Osteopathic Physicians Internal Medicine Adolescent Medicine

NPI
1386658128
CMS profile
334690
Location
MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$613.59

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $613.59 23

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AWAWU E IGBINADOLOR

NPI 1386658128 · CMS profile ID 334690

Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine

MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386658128?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386658128?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386658128?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1386658128?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $613.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $0.7512/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810733495 CMS
Novo Nordisk Inc $15.2612/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810889689 CMS
Lilly USA, LLC $14.5410/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818897803 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $83.4509/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850244459 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.3309/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763665672 CMS
Abbott Laboratories $12.6309/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833807545 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.0009/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789047609 CMS
Novo Nordisk Inc $113.7809/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811263033 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.9508/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819986945 CMS
Novo Nordisk Inc $19.0008/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811550593 CMS
Abbott Laboratories $22.4408/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833807543 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.7608/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789078699 CMS
PFIZER INC. $5.9308/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833565011 CMS
Teva Pharmaceuticals USA, Inc. $16.7108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839636871 CMS
AstraZeneca Pharmaceuticals LP $11.6307/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829564917 CMS
Abbott Laboratories $16.2907/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833807547 CMS
Lilly USA, LLC $15.4206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818965957 CMS
AstraZeneca Pharmaceuticals LP $16.2006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829636431 CMS
Novo Nordisk Inc $101.5705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811550587 CMS
AstraZeneca Pharmaceuticals LP $18.5005/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830055215 CMS
Novo Nordisk Inc $12.8104/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811759051 CMS
AstraZeneca Pharmaceuticals LP $18.1303/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829381643 CMS
GlaxoSmithKline, LLC. $16.5102/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803032791 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $825.59 19
PY2020 $250.77 11
PY2021 $613.59 23
PY2022 $635.48 38
PY2023 $1,376.29 8
PY2024 $3,264.02 14
PY2025 $15.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,807,545.77 332
PY2024 Recipient $24,803.18 2
PY2024 Principal investigator $5,575,092.65 467
PY2023 Recipient $5,441.70 12
PY2023 Principal investigator $4,002,304.15 759
PY2022 Recipient $99,385.00 2
PY2022 Principal investigator $3,185,482.26 500
PY2021 Recipient $421,014.16 3
PY2021 Principal investigator $3,556,229.85 34
PY2020 Recipient $145,488.66 2
PY2019 Principal investigator $9,471.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

502 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,854.35 12/31/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 917531447
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,386.29 12/31/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 917532025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124207
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $1,487.70 12/29/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237725
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,300.00 12/27/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217121
Principal investigator 1 PFIZER INC. $734.40 12/27/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949772043
Principal investigator 1 Mylan Specialty L.P. $5,627.53 12/23/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28,611.00 12/21/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124073
Principal investigator 1 PFIZER INC. $8,404.56 12/21/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772475
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 12/21/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350851
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $3,900.00 12/20/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237709
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $900.00 12/20/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237715
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $1,603.00 12/20/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237719
Principal investigator 1 PFIZER INC. $55.89 12/20/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763231
Principal investigator 1 SANOFI US SERVICES INC. $4,561.02 12/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618739
Principal investigator 1 PFIZER INC. $12,517.47 12/17/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949771737
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,030.00 12/16/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217119
Principal investigator 1 PFIZER INC. $17,250.00 12/16/2022 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949771951
Principal investigator 1 PFIZER INC. $19,028.79 12/16/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772085
Principal investigator 1 PFIZER INC. $62,081.65 12/13/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949771949
Principal investigator 1 PFIZER INC. $58,816.26 12/10/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772041
Principal investigator 1 Janssen Pharmaceuticals, Inc $8,075.00 12/05/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217125
Principal investigator 1 PFIZER INC. $12,109.23 12/03/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124429
Principal investigator 1 PFIZER INC. $37.26 11/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763109
Principal investigator 1 PFIZER INC. $19,919.56 11/23/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949778945
Principal investigator 1 Mylan Specialty L.P. $1,031.04 11/22/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566551
Principal investigator 1 PFIZER INC. $243.20 11/22/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949779053
Principal investigator 1 PFIZER INC. $37.26 11/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763107
Principal investigator 1 PFIZER INC. $4,000.00 11/18/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949779283
Principal investigator 1 Partner Therapeutics, Inc. $7,605.00 11/18/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517827
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,564.22 11/18/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350845
Principal investigator 1 PFIZER INC. $8,640.00 11/17/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949778915
Principal investigator 1 PFIZER INC. $18.63 11/16/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763037
Principal investigator 1 PFIZER INC. $1,216.00 11/09/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949778913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $72,338.40 11/04/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124071
Principal investigator 1 SANOFI US SERVICES INC. $4,584.62 11/02/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124405
Principal investigator 1 PFIZER INC. $18.63 10/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949763035
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,865.00 10/26/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217115
Principal investigator 1 PFIZER INC. $55.89 10/26/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763033
Principal investigator 1 PFIZER INC. $15,735.20 10/21/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949726031
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $250.00 10/18/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237697
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $8,800.00 10/18/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237703
Principal investigator 1 PFIZER INC. $3,000.00 10/14/2022 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949793875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9.45 10/10/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910124087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,320.00 09/21/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123785
Principal investigator 1 PFIZER INC. $4,147.20 09/21/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949793693
Principal investigator 1 Eli Lilly and Company $349,814.00 09/13/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917834249
Principal investigator 1 SANOFI US SERVICES INC. $2,000.96 09/12/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618703
Principal investigator 1 PFIZER INC. $3,993.60 09/09/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949793691
Principal investigator 1 Partner Therapeutics, Inc. $149.25 09/09/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517685
Principal investigator 1 Partner Therapeutics, Inc. $71.80 09/09/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517687
Principal investigator 1 Partner Therapeutics, Inc. $72,915.84 09/09/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517741
Principal investigator 1 SANOFI US SERVICES INC. $2,962.08 09/06/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618667
Principal investigator 1 SANOFI US SERVICES INC. $10,750.00 09/06/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618679
Principal investigator 1 SANOFI US SERVICES INC. $1,481.04 09/06/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618691
Principal investigator 1 SANOFI US SERVICES INC. $6,154.73 09/06/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618727
Principal investigator 1 SANOFI US SERVICES INC. $15,786.24 09/06/2022 Non-covered Recipient Entity
Monroe Biomedical Research, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935618749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124069
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,955.00 08/26/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217111
Principal investigator 1 Mylan Specialty L.P. $2,431.87 08/25/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565689
Principal investigator 1 PFIZER INC. $499.20 08/23/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949803221
Principal investigator 1 PFIZER INC. $4,096.00 08/10/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949802059
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $1,262.00 08/09/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $45,721.80 08/03/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123793
Principal investigator 1 PFIZER INC. $26,958.00 08/03/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949800809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124043
Principal investigator 1 PFIZER INC. $26,534.40 07/27/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949807355
Principal investigator 1 PFIZER INC. $24,331.00 07/27/2022 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949807379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,500.00 07/25/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 07/25/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123791
Principal investigator 1 Janssen Pharmaceuticals, Inc $78,879.00 07/22/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217107
Principal investigator 1 Mylan Specialty L.P. $2,875.40 07/22/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 07/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 07/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9.45 07/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 07/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910124045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50,193.00 07/13/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123787
Principal investigator 1 Eli Lilly and Company $4,289.00 07/13/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 917831569
Principal investigator 1 PFIZER INC. $1,843.20 07/13/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949807493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123763
Recipient Eli Lilly and Company $71,962.00 06/30/2022 Covered Recipient Physician A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917808341
Principal investigator 1 PFIZER INC. $40,742.40 06/30/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949814329
Principal investigator 1 Janssen Pharmaceuticals, Inc $57,733.00 06/20/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217103
Principal investigator 1 Mylan Specialty L.P. $7,752.97 06/17/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566557
Principal investigator 1 PFIZER INC. $12,249.60 06/16/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949814331
Principal investigator 1 Eli Lilly and Company $15,589.00 06/09/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917832487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28.35 06/08/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123477
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $5,000.00 06/02/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237691
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 06/02/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237859
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $85.00 06/02/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123673
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123683
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $7,003.00 05/24/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237853
Principal investigator 1 Janssen Pharmaceuticals, Inc $41,675.00 05/20/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 05/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 05/19/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123685
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/16/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237849
Principal investigator 1 PFIZER INC. $13,050.00 05/13/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949744493
Principal investigator 1 Janssen Pharmaceuticals, Inc $850.00 05/11/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217095
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $539.00 05/09/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237843
Principal investigator 1 Mylan Specialty L.P. $7,996.04 05/06/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566745
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237803
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237809
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $595.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237815
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237819
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237825
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237831
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/05/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237837
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $85.00 05/02/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237787
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/02/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237793
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 05/02/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123657
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $255.00 04/28/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237753
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $85.00 04/28/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237759
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $85.00 04/28/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237765
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 04/28/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237771
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 04/28/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237777
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $325.00 04/28/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237781
Principal investigator 1 PFIZER INC. $1,916.80 04/27/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949707293
Principal investigator 1 Janssen Pharmaceuticals, Inc $36,394.00 04/25/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217091
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $216.75 04/21/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350839
Principal investigator 1 Janssen Pharmaceuticals, Inc $14,100.00 04/20/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217087
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $995.00 04/18/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237743
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $135.00 04/18/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237749
Principal investigator 1 Mylan Specialty L.P. $9,004.04 04/13/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565695
Recipient Eli Lilly and Company $27,423.00 04/08/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917808241
Principal investigator 1 Partner Therapeutics, Inc. $4,510.93 04/08/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517473
Principal investigator 1 Partner Therapeutics, Inc. $41,780.37 04/08/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517499
Principal investigator 1 Eli Lilly and Company $395,858.00 04/05/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917827155
Principal investigator 1 Mylan Specialty L.P. $4,500.00 04/05/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123447
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,894.65 03/31/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350833
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,424.00 03/28/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217083
Principal investigator 1 AstraZeneca Pharmaceuticals LP $80,527.20 03/18/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 917532061
Principal investigator 1 Janssen Pharmaceuticals, Inc $84,696.00 03/18/2022 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885217079
Principal investigator 1 Mylan Specialty L.P. $1,437.70 03/07/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565457
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,510.05 03/03/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 03/01/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123467
Principal investigator 1 PFIZER INC. $8,193.60 02/23/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949708754
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $216.75 02/23/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350821
Principal investigator 1 AstraZeneca Pharmaceuticals LP $96,349.40 02/18/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 917531765
Principal investigator 1 PFIZER INC. $56.62 02/15/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949814327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $600.00 02/14/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/14/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/14/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/14/2022 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910123475
Principal investigator 1 Mylan Specialty L.P. $7,566.34 02/10/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566343
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,000.00 02/10/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350809
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 02/10/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350815
Principal investigator 1 PFIZER INC. $79.00 02/07/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949814881
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,660.90 02/03/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350803
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $77,862.60 02/01/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237685
Principal investigator 1 PFIZER INC. $113.80 01/12/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949813845
Principal investigator 1 PFIZER INC. $920.00 01/12/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949813847
Principal investigator 1 Eli Lilly and Company $5,013.00 01/11/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917832347
Principal investigator 1 Partner Therapeutics, Inc. $11,025.00 01/11/2022 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 916517485
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $475.00 01/10/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237737
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,410.15 01/07/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350793
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,444.15 01/07/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 942350799
Principal investigator 1 Novartis Pharmaceuticals Corporation $223,225.74 01/05/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH CQVA149A2350
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ENSOVIBEP (MP0420) IN AMBULATORY ADULT PATIENTS WITH SYMPTOMATIC COVID-19 No dispute reported 06/30/2026 910071455
Principal investigator 1 PFIZER INC. $1,520.00 01/04/2022 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949708740
Principal investigator 1 ADAMIS PHARMACEUTICALS CORPORATION $515.00 01/03/2022 Non-covered Recipient Entity
WCG IRB
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 954237731
Principal investigator 1 Eli Lilly and Company $180,365.00 01/03/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 917829431
Principal investigator 1 Eli Lilly and Company $426,981.00 01/03/2022 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 917831387